SecBot SecBot
8-K ·Filed Apr 9, 2026

IDYA

IDEAYA Biosciences, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago SEC0001193125-26-148777
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Traders should monitor upcoming clinical trial milestones and data readouts, as success could validate IDE849's potential and lead to future partnerships or accelerated development. However, no immediate revenue or financial impact is expected.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.00
T+0 close · Apr 9, 2026 · via day close
Latest settled
+27.00%
T+60 · $39.37
Vs SPY
+16.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $31.00entry
  2. T+1 · 7mo ago −1.61%α −1.55% · $30.50
  3. T+5 · 7mo ago +4.87%α +1.69% · $32.51
  4. T+20 · 6mo ago −7.29%α −14.86% · $28.74
  5. T+60 · 4mo ago +27.00%α +16.22% · $39.37
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

IDEAYA Biosciences announced a clinical collaboration with AstraZeneca to evaluate its investigational drug IDE849 in combination with AstraZeneca's Imfinzi for treating extensive-stage small cell lung cancer. The study will be globally sponsored by IDEAYA, with AstraZeneca supplying the drug.

Key Facts

  • IDEAYA Biosciences entered into a clinical collaboration agreement with AstraZeneca on April 8, 2026.
  • The collaboration will evaluate IDE849 (a DLL3 TOP1 antibody-drug conjugate) in combination with Imfinzi (durvalumab) in extensive-stage small cell lung cancer (SCLC).
  • IDEAYA will sponsor the global Phase 1 clinical trial, while AstraZeneca will supply Imfinzi.
  • The trial is part of a broader multi-site global Phase 1 study in DLL3 upregulated solid tumors, including SCLC, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma.

Financial Impact

Undisclosed financial terms; IDEAYA will sponsor the study, and AstraZeneca will supply Imfinzi.

R&D expensesclinical development timeline

Risk Factors

  • Clinical trial may not meet efficacy or safety endpoints.
  • Regulatory delays or trial enrollment challenges could slow development.
  • Dependence on third-party collaborator (AstraZeneca) for supply and trial success.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-148777
Document: 0001193125-26-148777-index-headers.html0001193125-26-148777
Document: 0001193125-26-148777-index.html0001193125-26-148777
Document: 0001193125-26-148777.txt0001193125-26-148777

Track record

13 reports on IDYA

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  2. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  3. Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
  4. Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
  6. Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
  7. Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
  8. Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
  10. May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (9h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 9, 2026